Receiving any other investigational agent that would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Currently receiving or have received any other investigational agent considered as a treatment for the primary neoplasm =< days prior to registration
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm =< days prior to registration
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm or used an investigational device =< weeks from registration
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm; NOTE: Bisphosphonates are considered to be supportive care rather than therapy and are allowed while on protocol treatment
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any investigational agent, that would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Currently receiving or have received any other investigational agent considered as a treatment for the primary neoplasm =< days or within half-lives (whichever is shorter) of the agent prior to registration
Receiving any other investigational agent, which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm; patients must be >= weeks from prior anti-lymphoma therapy; the use of steroids and/or rituximab up to week prior to registration for management of symptoms is allowed
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Currently receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent =< weeks prior to registration which would be considered as treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent that would be considered a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent that would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Currently receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm